₹ 837.41 Cr
2.3%
BSE Healthcare TRI
INF209KB1N91
1000.0
1000.0
100
Mr. Dhaval Shah
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth | 1.05 | 21.48 | 12.69 |
| Benchmark | - | - | - |
Equity
Debt
Others
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 13.47 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 7.14 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 6.08 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.71 |
| JB Chemicals & Pharmaceuticals Limited | 4.51 |
| ABBOTT INDIA LIMITED EQ | 4.48 |
| AJANTA PHARMA LIMITED EQ NEW FV RS. 2/- | 4.28 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 4.11 |
| FORTIS HEALTHCARE LIMITED. EQ | 3.99 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 3.94 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 96.47 |
| Financial Services | 1.43 |
| Chemicals | 0.9 |